Retatrutide is going to change a lot of people's lives over the next few years. The trial data is striking — north of 25% body weight loss at a year — and the drug is on track for FDA filing in the late 2020s. Most of what's currently written about it online is a mix of press releases, forum speculation, and pharmacy-affiliate spam.

glp3.wiki is an attempt to publish grounded, well-sourced reference content for retatrutide and the wider GLP class before the SEO-spam version of this category fills the gap. The articles cite primary trial data (NEJM, ClinicalTrials.gov, Lilly investor relations) and are reviewed when new data lands.

Why a wiki, not a blog

Reference content compounds differently from posts. A blog post about a Phase 2 readout is stale the moment a Phase 3 readout publishes. A reference article about how retatrutide works is updated, not replaced. The wiki shape — durable pages, versioned updates, cross-links between related topics — is the right format for a drug that will be in the news for years.

What the AI does

Hero illustrations are generated with Gemini's nanobanana model in a consistent watercolor style. The structured data that feeds search-result rich snippets is built from a content registry. Article drafts are co-written; everything published is read by a human and cross-checked against the source.